Objectives: The activity of ceftazidime/avibactam was assessed against 5716 Pseudomonas aeruginosa isolates collected from 96 medical centres in 18 European countries as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme from 2012 to 2015. Activity was analysed against subsets of isolates based on resistance phenotypes and b-lactamase content.
Introduction
Pseudomonas aeruginosa is an opportunistic pathogen that commonly causes nosocomial infections. 1, 2 Many isolates show decreased susceptibility to antipseudomonal drugs, including b-lactams. Cephalosporin resistance is most frequently mediated by stable derepression of the chromosomally encoded AmpC cephalosporinase, whereas carbapenem resistance additionally requires decreased production of the OprD porin or upregulation of efflux transporters. [3] [4] [5] [6] Resistance can also be mediated by transmissible b-lactamases, but isolates carrying these are still relatively uncommon in Europe. [7] [8] [9] Avibactam is a non-b-lactam b-lactamase inhibitor with activity against Ambler class A, class C and some class D b-lactamases. 10, 11 Avibactam restores the activity of ceftazidime against OprDdeficient P. aeruginosa isolates that hyperproduce AmpC. 6, 11, 12 Ceftazidime/avibactam appears less active against some isolates carrying VEB-type ESBLs, which may co-carry avibactam-insensitive b-lactamases or harbour additional, non-b-lactamase-mediated mechanisms of resistance; ceftazidime/avibactam is active (MICs ,2 mg/L) in vitro against several VEB subtypes when produced by Enterobacteriaceae. [12] [13] [14] Ceftazidime/avibactam is not active against P. aeruginosa carrying MBLs and does not reverse resistance mediated by up-regulated efflux. 6, 10, 12, 15 Reduced susceptibility is correlated with resistance to cefepime, ceftazidime and piperacillin/ tazobactam in meropenem-non-susceptible isolates that do not carry acquired b-lactamases 16 and is also conferred by AmpC b-lactamases with amino acid substitutions or small deletions in the V C The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com. omega loop. 17 Additional undefined resistance mechanisms may also exist. 6, 13, 15, 18 In 2016, ceftazidime/avibactam was approved in the EU for treatment of complicated intra-abdominal and complicated urinary tract infections including pyelonephritis, hospital-acquired and ventilator-associated pneumonia and infections caused by aerobic Gram-negative bacteria resistant to other available agents in adult patients. 19 This study reports the activity of ceftazidime/avibactam and comparator agents against isolates of P. aeruginosa collected in 18 European countries as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme from 2012 to 2015.
Materials and methods
Isolate collection, antimicrobial susceptibility testing and screening for b-lactamase genes are described in the Supplementary data (available as Supplementary data at JAC Online).
Results
Susceptibility to ceftazidime/avibactam (MICs 8 mg/L) was 92.4% (MIC 90 " 8 mg/L) among the 5716 isolates of P. aeruginosa collected and exceeded the susceptibilities to all other tested agents except colistin (99.6% susceptible) ( Kazmierczak et al.
increased to 95.9% among the subset of MBL-negative isolates; as expected, ceftazidime/avibactam was not active against MBLpositive isolates (2.8% susceptible) and colistin was the only tested agent with notable activity against this difficult-to-treat subset (Table 1) . Susceptibility to ceftazidime/avibactam ranged from 74.6% to 99.6% across the region and was .90% in all countries except the Czech Republic, Greece, Romania and Russia ( Figure 1 and Tables S1 to S18). Although activity was increased 2-to 4-fold against MBL-negative isolates from these four countries, MIC 90 values remained above the susceptibility breakpoint against isolates collected in Russia and Romania; nonetheless, ceftazidime/avibactam remained the second most active agent after colistin against these isolates (Tables S13 and S14) .
A total of 1573 meropenem-non-susceptible isolates (MICs 4 mg/L) were screened for the presence of acquired b-lactamase genes (Table S19) . Of these, 211 isolates (13.4%) carried MBLs, with or without acquired serine b-lactamases, 44 isolates (2.8%) carried GES carbapenemases, 59 isolates (3.8%) carried ESBLs and 6 isolates (0.4%) carried only TEM-type broad-spectrum b-lactamases. One additional MBL-positive isolate, collected in Turkey (meropenem MIC " 2 mg/L) was also identified during the course of this study (Tables 1, S17 , S19 and S36, and Figures S1 and S2) . No acquired b-lactamase genes were found in 1253 meropenemnon-susceptible isolates (79.7%), which were inferred to harbour alterations in OprD or efflux pump expression combined with AmpC hyperproduction. 5, 6 Therefore, in contrast to the Enterobacteriaceae, carbapenem non-susceptibility in P. aeruginosa does not appear to be mainly mediated by carbapenemase production.
The distribution of b-lactamases among molecularly characterized isolates from each country is described in Figures S1 and S2 , and Tables S20 to S37. ESBLs were detected in ,10% of isolates from all countries except Romania, with PER-and VEB-type enzymes found most commonly ( Figure S1 ). The prevalence of carbapenemases also varied by country, with VIM-type, GES-type and IMP-type carbapenemases detected in isolates collected from 15, 3 and 3 countries, respectively ( Figure S2 ). The highest proportions of MBL-positive isolates were found among P. aeruginosa from Russia (16.4%), Greece (12.9%), Romania (8.2%), the Czech Republic (5.6%) and Belgium (4.6%) and represented ,3% of isolates collected in other countries (Tables S20 to S37 Ceftazidime/avibactam against P. aeruginosa from Europe JAC no acquired b-lactamases (Table S19 ). Ceftazidime/avibactam was not active against MBL-positive isolates and also demonstrated reduced activity against some MBL-negative, ESBL-positive isolates (22.0% susceptible). This subset of 59 isolates included those carrying PER-1 (n " 21, 38.1% susceptible), VEB-1A (n " 21, 0.0% susceptible), VEB-1 (n " 2, 0.0% susceptible), GES-1 (n " 12, 33.3% susceptible), GES-7 (n " 1, 0.0% susceptible), SHV-2A (n " 1, 100% susceptible) and SHV-5 (n " 1, 0.0% susceptible). A total of 23.1% of collected isolates tested as non-susceptible to ceftazidime, with percentages of non-susceptible isolates ranging from 7.5% to 42.2% across the region ( Figure S3 and Table S38 ). Susceptibility of ceftazidime-non-susceptible isolates to ceftazidime/avibactam was 67.2% and increased to 79.6% against the set of ceftazidime-non-susceptible, MBL-negative isolates; at the country level, susceptibility ranged from 37.1% to 94.1% and increased by 0.8%-38.0% when MBL-positive isolates were excluded. Colistin was the only agent that was consistently more active than ceftazidime/avibactam against all isolates and against MBL-negative, ceftazidime-non-susceptible isolates at regional and country levels (.96% susceptible) (Tables S1 to S18 and S38).
The percentage of meropenem-non-susceptible P. aeruginosa isolates collected was 27.5% and ranged from 6.6% to 46.6% ( Figure S4 and Table S38 ). Overall, 74.0% of meropenem-nonsusceptible and 85.1% of MBL-negative, meropenem-non-susceptible isolates remained susceptible to ceftazidime/avibactam, which was exceeded only by susceptibility to colistin (.99% susceptible) (Table S38 ). Susceptibility to ceftazidime/avibactam was lower than the regional average in Austria, Belgium, Greece, Russia and Romania and increased by 10.6%-35.7% when MBL-positive, meropenem-non-susceptible isolates were excluded (Tables S1,  S2 , S7, S13 and S14).
Ceftazidime/avibactam was the most active agent tested against 14 isolates of colistin-resistant P. aeruginosa (92.9% susceptible), compared with susceptibilities of ,65% for other tested agents ( Figure S5 and Table S38 ). Only one colistin-resistant isolate carrying VEB-1A, collected in Romania, was not susceptible to ceftazidime/avibactam or to any other tested agent (Table S13) . No MBL-positive colistin-resistant isolates were identified.
A total of 24.8% of collected isolates displayed an MDR phenotype, with MDR rates varying from 8.0% to 45.0% among the surveyed countries ( Figure S6 and Table S38 ). Of these, 69.9% of all and 81.6% of MBL-negative, MDR isolates remained susceptible to ceftazidime/avibactam, a higher percentage of susceptibility than observed for all other agents except colistin (99% susceptible). At the country level, susceptibility of MDR isolates to ceftazidime/ avibactam varied from 43.5% to 94.4% and increased to 55.6%#94.4% against MBL-negative, MDR isolates (Tables S1 to S18). Even in countries with relatively low susceptibilities (Russia and Romania), the percentages of susceptibility to ceftazidime/avibactam were still higher than susceptibilities observed for all other agents except colistin (Tables S13 and S14) .
Discussion
Ceftazidime/avibactam demonstrated potent in vitro activity against MDR isolates of P. aeruginosa and isolates non-susceptible to ceftazidime or meropenem that exceeded that of all tested comparators except colistin and was superior to all tested agents against colistin-resistant isolates. Ceftazidime/avibactam was not active against P. aeruginosa carrying MBLs and, as a result, reduced activity was observed in countries where MBL-positive isolates were more prevalent. In addition, 211 P. aeruginosa were identified that lacked the MBLs screened as part of this study but tested as non-susceptible to ceftazidime/avibactam. These isolates were encountered in all countries except the Netherlands and may harbour resistant b-lactamases not included in the testing algorithm, 12 AmpC mutations that make that enzyme less sensitive to avibactam 17, 18 or additional undetermined resistance mechanisms. 6, 13, 15, 16 The European Antimicrobial Resistance Surveillance Network (EARS-Net) monitors the antimicrobial susceptibilities of invasive pathogens collected from patients in 30 countries. 2 According to EARS-Net, 5.0% of P. aeruginosa isolates collected in 2015 were carbapenem resistant and 4.4% were resistant to all five drug classes under regular surveillance. 2 Although the results of this study cannot be directly compared with those of the EARS-Net, the overall patterns of resistance observed were similar, with higher resistance rates observed in southern and eastern Europe. Both studies reported high percentages of non-susceptibility for P. aeruginosa from Romania (ceftazidime, carbapenems or MDR), Greece (carbapenems and MDR) and Hungary (carbapenems). However, the high levels of resistance reported for Poland (ceftazidime, carbapenems or MDR) by the EARS-Net were not observed in this study. Likewise, the elevated resistance observed in the Czech Republic (ceftazidime, carbapenems or MDR) and Italy (carbapenems and MDR) reported in this study were not observed by the EARS-Net. 2 Differences in study design and patient population, as well as in the number and location of the participating medical centres, may account for variations in reported resistance rates between EARS-Net and the present study.
Infections caused by P. aeruginosa result in significant morbidity and mortality. 1 The promising activity of ceftazidime/avibactam allows it to be considered as an alternative for therapy against infections caused by P. aeruginosa that are resistant to other therapies, including ceftazidime, meropenem, colistin and multiple classes of agents.
